Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisone + aspirin is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Prednisone is a synthetic corticosteroid that suppresses inflammation and modulates immune responses by inhibiting multiple inflammatory pathways, including the suppression of pro-inflammatory gene expression via glucocorticoid receptor activation. Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), leading to reduced synthesis of prostaglandins and thromboxanes, which mediate pain, fever, inflammation, and platelet aggregation. This combination may be used in certain inflammatory or autoimmune conditions but carries an increased risk for gastrointestinal side effects such as bleeding or ulceration due to additive effects on the GI mucosa[2][4]. The use of both drugs together should be carefully monitored by healthcare professionals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisone + aspirin.